Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
NCT07919470, Not applicable, Not yet recruiting, Peking University People's Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT | ClinicalTrials.gov |
| NCT number | NCT07919470 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 180 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Peking University People's Hospital | ClinicalTrials.gov |
| Conditions | Acute Lymphoblastic Leukemia, Hematopoietic Stem Cell Transplantation | ClinicalTrials.gov |
| Interventions | Chemotherapy-based Conditioning Regimen, TBI-based conditioning | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | 1-Year Leukemia-Free Survival (LFS) | 12 months post-hematopoietic stem-cell infusion] | Time from stem-cell infusion to leukemia relapse or death from any cause, whichever occurs first. | ClinicalTrials.gov |
| Secondary | 1-Year Treatment-Related Mortality (TRM) | 12 months post-transplantation | Cumulative incidence of non-relapse-related death after transplantation (competing risk: leukemia relapse). | ClinicalTrials.gov |
| Secondary | Cumulative Incidence of Relapse (CIR) | 1-year, 2-year, 3-year post-transplantation | Cumulative probability of hematologic or molecular leukemia relapse with death as competing risk event. | ClinicalTrials.gov |
| Secondary | Cumulative Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) | Day 100, 1-year, 3-year post-transplantation | Cumulative incidence of grade II-IV, grade III-IV acute GVHD (100-day landmark); cumulative incidence of mild/moderate/severe chronic GVHD within 3 years, graded according to NIH GVHD consensus criteria. | ClinicalTrials.gov |
| Secondary | Overall Survival (OS) | 1-year, 2-year, 3-year post-transplantation | Time from stem-cell infusion until death from any cause. | ClinicalTrials.gov |
| Secondary | Conditioning-related organ toxicities | Conditioning start up to post-transplant day +30 | Incidence of grade 1-4 cardiac, hepatic, renal, gastrointestinal and mucosal toxicities from conditioning initiation up to day +30 post-transplantation, graded by WHO organ-toxicity scale. | ClinicalTrials.gov |
| Secondary | Hematopoietic engraftment | Day 30 and Day 90 post-transplantation | Neutrophil engraftment: sustained ANC ≥ 0.5 × 10⁹/L for three consecutive days; platelet engraftment: sustained PLT ≥ 20 × 10⁹/L without transfusion support for seven consecutive days. | ClinicalTrials.gov |
| Secondary | Molecular/Flow-MRD status post-transplant | +1, +2, +3, +6, +12 months post-transplantation | MRD positive defined as flow cytometry ≥ 0.01 %; or detectable quantifiable fusion-gene / Ig-TCR / NGS clonal signal above assay sensitivity threshold at serial follow-up time-points. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)